Posts in tag

Allergy


Almost all Australians with moderate-to-severe allergic rhinitis are experiencing disrupted sleep and its impact on health and wellbeing Mylan Health has released the results of its YouGov Galaxy research in …

Anaesthetists are calling for a ban, or an upschedule to Prescription Only, for cough medicines containing pholcodine Dr Paul McAleer, a specialist anaesthetist and chair of the multidisciplinary organisation The …

People with hayfever are being urged to get tested for undiagnosed asthma, as a new study reveals the condition’s impact Associate Professor Cenk Suphioglu, the head of Deakin University’s pollen …

A UK health authority has asked health practitioners to be sceptical of claimed penicillin allergies Patients who incorrectly believe they are allergic to penicillin may be placing themselves at unnecessary …

While Mylan’s EpiPen has dominated the epinephrine injection market for years, two new contenders are planning to launch versions… could these help relieve shortages? With no generic versions and few …

Asthma is much more than just the wheeze when symptoms appear, writes Louis Roller More than two million Australians have asthma – about one in 10 adults and about one …

Stakeholders have called for more work to be done to manage allergies, saying $10 million is required over the next five years An event held at Parliament House, attended by …

A recent retrospective study of healthcare workers assessed in an Australian tertiary referral dermatology clinic showed that 49.7% had experienced allergic contact dermatitis Associate Professor Rosemary Nixon AM, who helps …

Australian scientists have helped to uncover 41 genetic regions, which are estimated to account for about 40% of the genetic risk of hayfever A large international study, including contributions from …

Incorrect antibiotic allergy labels pose a significant public health issue, says an antimicrobial stewardship expert More needs to be done to ensure Australia’s most vulnerable patients are not incorrectly diverted …

Debbie Rigby takes a look at the latest in research news  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT) A 24-week randomised controlled, comparative effectiveness trial …

While Pfizer is working to achieve ongoing availability, it reportedly cannot commit to a specific time when the supply constraint will be fully resolved Mylan/Alphapharm, the sponsor of EpiPens, has …